| Code | CSB-RA011590MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to APG-777, targeting interleukin-13 (IL-13), a key type 2 cytokine involved in allergic and inflammatory responses. IL-13 is primarily produced by activated T helper 2 (Th2) cells, innate lymphoid cells, and other immune cells, where it plays a central role in regulating IgE synthesis, mucus hypersecretion, airway hyperresponsiveness, and tissue remodeling. Dysregulated IL-13 signaling is implicated in the pathogenesis of asthma, atopic dermatitis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and various allergic disorders, making it an important therapeutic target for these conditions.
APG-777 is a preclinical/early clinical-stage, humanized monoclonal antibody targeting IL-13. It has a high affinity for and specifically binds to IL-13 that is overly active in the body, neutralizing the abnormal activation of downstream signaling pathways such as JAK-STAT. This helps to alleviate inflammatory responses, relieve itching, and promote skin barrier repair. This biosimilar antibody provides researchers with a cost-effective alternative for studying IL-13 biology, exploring disease mechanisms, and conducting preclinical investigations into type 2 immune responses. It serves as a valuable reagent for immunology research, enabling detailed characterization of IL-13 function in various experimental models.
There are currently no reviews for this product.